Cell-free DNA screening

cfDNA Basics - Fetal DNA Sneak Peek

• What it is: Small fragments of circulating DNA in the maternal bloodstream, a mix of maternal and placental DNA.
• Source: Primarily from apoptosis of placental trophoblasts, releasing fetal genetic material.
• Timing: Can be reliably detected as early as 10 weeks gestation.
• Fetal Fraction (FF): The proportion of cfDNA that is of fetal origin.
  • A result requires a minimum FF, typically >4%, for accuracy.

⭐ High-yield fact: A low fetal fraction, which can be caused by high maternal BMI, is a primary reason for cfDNA test failure or an inconclusive result.

The NIPS Test - How, When & What

• What: Non-Invasive Prenatal Screening (NIPS) analyzes cell-free DNA (cfDNA) from the placenta circulating in maternal blood. Primarily screens for common fetal aneuploidies.
• When: Can be performed as early as 10 weeks gestation.
• Screens For:
  • Trisomy 21 (Down syndrome)
  • Trisomy 18 (Edwards syndrome)
  • Trisomy 13 (Patau syndrome)
  • Sex chromosome aneuploidies (e.g., Turner syndrome)

⭐ NIPS is a screening test, not diagnostic. A high-risk result requires confirmation with diagnostic testing like chorionic villus sampling (CVS) or amniocentesis.

Performance & Pitfalls - Reading Between the Lines

• Excellent detection rates (DR) for common trisomies: >99% for Trisomy 21, ~97% for T18, ~92% for T13.
  • Lower performance for sex chromosome aneuploidies & microdeletions.
• ⚠️ It remains a screening test; positive results mandate diagnostic testing (amniocentesis/CVS).
• Pitfalls:
  • False Positives (FP): Confined placental mosaicism, vanishing twin, maternal malignancy.
  • False Negatives (FN) / No-Call Results: Often due to low fetal fraction (<4%). A no-call result itself is a soft marker for aneuploidy.

⭐ Positive Predictive Value (PPV) is critically dependent on a priori risk (i.e., maternal age, other screening). A positive result in a low-risk patient has a significantly lower PPV than in a high-risk patient.

Clinical Pathway - From Result to Action

• Primary Action Driver: Test result (high vs. low risk) and patient counseling are paramount.
• Inconclusive/No-Call Result: Occurs in 1-8% of cases, often due to low fetal fraction. Options include redraw, offering diagnostic testing, or ultrasound.

⭐ cfDNA is a screening, not diagnostic, tool. The Positive Predictive Value (PPV) varies greatly with aneuploidy prevalence. A high-risk result for Trisomy 21 in a 40-year-old may have a PPV of >90%, but for a rare condition, it could be <10%.

High‑Yield Points - ⚡ Biggest Takeaways

• Cell-free DNA (cfDNA) is a non-invasive prenatal screening test analyzing fetal DNA in maternal blood, offered at ≥10 weeks gestation.
• It demonstrates high sensitivity and specificity for common fetal aneuploidies, particularly trisomy 21.
• Remember, cfDNA is a screening test, not diagnostic; it indicates risk, but does not provide a definitive diagnosis.
• Positive results require confirmation with diagnostic testing like amniocentesis or chorionic villus sampling (CVS).
• Test failure can occur due to low fetal fraction.